메뉴 건너뛰기




Volumn 9, Issue 8, 2014, Pages 1146-1153

NCCTG N0821 (Alliance): A phase ii first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status

Author keywords

Bevacizumab; Elderly; Non small cell lung cancer; Nonsquamous histology; Survival

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PEMETREXED; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY; REDUCED FOLATE CARRIER; SLC19A1 PROTEIN, HUMAN; THYMIDYLATE SYNTHASE;

EID: 84905823267     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000217     Document Type: Article
Times cited : (8)

References (35)
  • 1
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 2
    • 37849052774 scopus 로고    scopus 로고
    • Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
    • Eastern Cooperative Oncology Group
    • Ramalingam SS, Dahlberg SE, Langer CJ, et al.; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
    • (2008) J Clin Oncol , vol.26 , pp. 60-65
    • Ramalingam, S.S.1    Dahlberg, S.E.2    Langer, C.J.3
  • 3
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 4
    • 70350225538 scopus 로고    scopus 로고
    • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: A randomised, double-blind, phase 3 study
    • Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
    • (2009) Lancet , vol.374 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3
  • 5
    • 34249843852 scopus 로고    scopus 로고
    • Survival without common toxicity criteria grade. Toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): A risk-benefit analysis
    • Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade . toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007;2:397-401.
    • (2007) J Thorac Oncol , vol.2 , pp. 397-401
    • Pujol, J.L.1    Paul, S.2    Chouaki, N.3
  • 6
    • 70249116447 scopus 로고    scopus 로고
    • Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer
    • Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-3289.
    • (2009) J Clin Oncol , vol.27 , pp. 3284-3289
    • Patel, J.D.1    Hensing, T.A.2    Rademaker, A.3
  • 7
    • 77449098773 scopus 로고    scopus 로고
    • Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced nonsmall- cell lung cancer: NCCTG and SWOG study N0426
    • Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced nonsmall- cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010;28:614-619.
    • (2010) J Clin Oncol , vol.28 , pp. 614-619
    • Adjei, A.A.1    Mandrekar, S.J.2    Dy, G.K.3
  • 8
    • 84863092492 scopus 로고    scopus 로고
    • VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials
    • Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012;13:724-733.
    • (2012) Lancet Oncol , vol.13 , pp. 724-733
    • Lambrechts, D.1    Claes, B.2    Delmar, P.3
  • 9
    • 53749093040 scopus 로고    scopus 로고
    • Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    • ECOG 2100
    • Schneider BP, Wang M, Radovich M, et al.; ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
    • (2008) J Clin Oncol , vol.26 , pp. 4672-4678
    • Schneider, B.P.1    Wang, M.2    Radovich, M.3
  • 10
    • 84862778659 scopus 로고    scopus 로고
    • Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy
    • Yin M, Liao Z, Yuan X, et al. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 2012;103:945-950.
    • (2012) Cancer Sci , vol.103 , pp. 945-950
    • Yin, M.1    Liao, Z.2    Yuan, X.3
  • 11
    • 69949111615 scopus 로고    scopus 로고
    • Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599
    • abstr8032
    • Zhang W, Dahlberg SE, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol 2009;27:abstr8032.
    • (2009) J Clin Oncol , vol.27
    • Zhang, W.1    Dahlberg, S.E.2    Yang, D.3
  • 12
    • 84867272757 scopus 로고    scopus 로고
    • Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer
    • Hu Q, Li X, Su C, et al. Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Exp Ther Med 2012;4:1010-1016.
    • (2012) Exp Ther Med , vol.4 , pp. 1010-1016
    • Hu, Q.1    Li, X.2    Su, C.3
  • 13
    • 84866173015 scopus 로고    scopus 로고
    • Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin
    • Tiseo M, Giovannetti E, Tibaldi C, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 2012;78:92-99.
    • (2012) Lung Cancer , vol.78 , pp. 92-99
    • Tiseo, M.1    Giovannetti, E.2    Tibaldi, C.3
  • 14
    • 65349091355 scopus 로고    scopus 로고
    • Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
    • Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-2045.
    • (2009) J Clin Oncol , vol.27 , pp. 2038-2045
    • Smit, E.F.1    Burgers, S.A.2    Biesma, B.3
  • 15
    • 77956268512 scopus 로고    scopus 로고
    • Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: A North Central Cancer Treatment Group-based exploratory study
    • Adjei AA, Salavaggione OE, Mandrekar SJ, et al. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol 2010;5:1346-1353.
    • (2010) J Thorac Oncol , vol.5 , pp. 1346-1353
    • Adjei, A.A.1    Salavaggione, O.E.2    Mandrekar, S.J.3
  • 16
    • 33845382806 scopus 로고
    • Nonparametric estimation for incomplete observations
    • Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.1    Meier, P.2
  • 17
    • 1542289011 scopus 로고    scopus 로고
    • Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials
    • Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004;14:73-96.
    • (2004) J Biopharm Stat , vol.14 , pp. 73-96
    • Sloan, J.A.1    Dueck, A.2
  • 18
    • 84655163441 scopus 로고    scopus 로고
    • A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/ bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer
    • Spigel DR, Hainsworth JD, Shipley DL, et al. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/ bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. J Thorac Oncol 2012;7:196-202.
    • (2012) J Thorac Oncol , vol.7 , pp. 196-202
    • Spigel, D.R.1    Hainsworth, J.D.2    Shipley, D.L.3
  • 19
    • 84875889240 scopus 로고    scopus 로고
    • Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
    • Gervais R, Robinet G, Clément-Duchêne C, et al. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. Lung Cancer 2013;80:185-190.
    • (2013) Lung Cancer , vol.80 , pp. 185-190
    • Gervais, R.1    Robinet, G.2    Clément-Duchêne, C.3
  • 20
    • 84875612797 scopus 로고    scopus 로고
    • Dose escalation study of carboplatin- pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer
    • Tamiya A, Tamiya M, Shiroyama T, et al. Dose escalation study of carboplatin- pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Ann Oncol 2013;24:980-985.
    • (2013) Ann Oncol , vol.24 , pp. 980-985
    • Tamiya, A.1    Tamiya, M.2    Shiroyama, T.3
  • 21
    • 84892454962 scopus 로고    scopus 로고
    • PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer
    • Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:4349-4357.
    • (2013) J Clin Oncol , vol.31 , pp. 4349-4357
    • Patel, J.D.1    Socinski, M.A.2    Garon, E.B.3
  • 22
    • 84886384997 scopus 로고    scopus 로고
    • Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials
    • abstr 8073
    • Langer CJ, Socinski MA, Patel JD, et al. Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): analyses based on age in the phase III PointBreak and E4599 trials. J Clin Oncol 2013;31:abstr 8073.
    • (2013) J Clin Oncol , vol.31
    • Langer, C.J.1    Socinski, M.A.2    Patel, J.D.3
  • 23
    • 28044463139 scopus 로고    scopus 로고
    • Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer
    • Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005;104:2449-2456.
    • (2005) Cancer , vol.104 , pp. 2449-2456
    • Zinner, R.G.1    Fossella, F.V.2    Gladish, G.W.3
  • 24
    • 19944426696 scopus 로고    scopus 로고
    • Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial
    • Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11(2 Pt 1):690-696.
    • (2005) Clin Cancer Res , vol.11 , Issue.2 PART 1 , pp. 690-696
    • Scagliotti, G.V.1    Kortsik, C.2    Dark, G.G.3
  • 25
    • 78650434724 scopus 로고    scopus 로고
    • Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer
    • Socinski MA, Raju RN, Stinchcombe T, et al. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5:1963-1969.
    • (2010) J Thorac Oncol , vol.5 , pp. 1963-1969
    • Socinski, M.A.1    Raju, R.N.2    Stinchcombe, T.3
  • 26
    • 80054911223 scopus 로고    scopus 로고
    • A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer
    • Rodrigues-Pereira J, Kim JH, Magallanes M, et al. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:1907-1914.
    • (2011) J Thorac Oncol , vol.6 , pp. 1907-1914
    • Rodrigues-Pereira, J.1    Kim, J.H.2    Magallanes, M.3
  • 27
    • 84885924300 scopus 로고    scopus 로고
    • PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    • Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-2902.
    • (2013) J Clin Oncol , vol.31 , pp. 2895-2902
    • Paz-Ares, L.G.1    De Marinis, F.2    Dediu, M.3
  • 28
    • 39749096242 scopus 로고    scopus 로고
    • VEGF polymorphisms and survival in early-stage non-small-cell lung cancer
    • Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-862.
    • (2008) J Clin Oncol , vol.26 , pp. 856-862
    • Heist, R.S.1    Zhai, R.2    Liu, G.3
  • 29
    • 79958261031 scopus 로고    scopus 로고
    • Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    • Loupakis F, Ruzzo A, Salvatore L, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 2011;11:247.
    • (2011) BMC Cancer , vol.11 , pp. 247
    • Loupakis, F.1    Ruzzo, A.2    Salvatore, L.3
  • 30
    • 70349585443 scopus 로고    scopus 로고
    • Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer
    • Masago K, Fujita S, Kim YH, et al. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci 2009;100:1917-1922.
    • (2009) Cancer Sci , vol.100 , pp. 1917-1922
    • Masago, K.1    Fujita, S.2    Kim, Y.H.3
  • 31
    • 84859726033 scopus 로고    scopus 로고
    • VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma
    • Kim MK, Suh C, Chi HS, et al. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Sci 2012;103:497-503.
    • (2012) Cancer Sci , vol.103 , pp. 497-503
    • Kim, M.K.1    Suh, C.2    Chi, H.S.3
  • 32
    • 77953968068 scopus 로고    scopus 로고
    • Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
    • Kim DH, Xu W, Kamel-Reid S, et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 2010;21:1179-1188.
    • (2010) Ann Oncol , vol.21 , pp. 1179-1188
    • Kim, D.H.1    Xu, W.2    Kamel-Reid, S.3
  • 33
    • 77955240423 scopus 로고    scopus 로고
    • Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
    • Jain L, Sissung TM, Danesi R, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010;29:95.
    • (2010) J Exp Clin Cancer Res , vol.29 , pp. 95
    • Jain, L.1    Sissung, T.M.2    Danesi, R.3
  • 34
    • 81255160848 scopus 로고    scopus 로고
    • Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study
    • Garcia-Donas J, Esteban E, Leandro-García LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011;12:1143-1150.
    • (2011) Lancet Oncol , vol.12 , pp. 1143-1150
    • Garcia-Donas, J.1    Esteban, E.2    Leandro-García, L.J.3
  • 35
    • 67149114893 scopus 로고    scopus 로고
    • Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity
    • Peters EJ, Kraja AT, Lin SJ, et al. Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet Genomics 2009;19:399-401.
    • (2009) Pharmacogenet Genomics , vol.19 , pp. 399-401
    • Peters, E.J.1    Kraja, A.T.2    Lin, S.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.